GLP-1 Statistics Blog GLP-1 Statistics Blog
Industry Insights

GLP-1s have become half of the UK diabetes budget. Here is what the prescribing data shows.

4th November 2026

|

Gabriel Warwick

Two years ago the GLP-1 story was a supply story – Shortages, rationing, pharmacies turning patients away. Today it is a spending story. Across the four UK nations, primary care prescribing for diabetes and obesity reached £2.39bn in the latest twelve months, up 15% on the year before. Half of that, £1.19bn, is now GLP-1 and dual agonists. That class has more than doubled in cost in a single year.

For context, all primary care medicines spend grew just over 5% in the same period. Diabetes and obesity now account for 17% of everything the NHS spends on primary care prescribing, and GLP-1s are the reason.

One Molecule Is Doing Most of The Work

Tirzepatide, Lilly’s dual GIP and GLP-1 agonist sold as Mounjaro, was dispensed 4.1 million times in the last twelve months, nearly double the year before, at a cost of £947m. It now accounts for 60% of GLP-1 class volume. In England, Mounjaro alone is 44% of class items, ahead of Ozempic at 11% and Rybelsus at 10%.

Semaglutide is still growing, but slowly, up 5% by items. The older agents are being squeezed out. Dulaglutide fell 18% and exenatide fell 87%. That is substitution within the class, not patients stopping treatment.

Growth Is Uneven Across the Country

Scotland saw the fastest GLP-1 growth of the four nations at 53%, Wales the slowest at 30%. Within England the spread between integrated care boards is just as wide. North East and North Cumbria, the largest ICB by volume, grew 53% year on year. Hampshire and Isle of Wight grew 52%. Cheshire and Merseyside, third largest, grew only 20%. Where a patient lives still shapes how likely they are to be on one of these drugs through their GP.

One caveat: these figures are primary care only. ICBs running large specialist weight management services will look smaller here than they really are, and the weight management indication is still mostly outside the GP prescribing data. The old obesity class, essentially orlistat, is flat at 629 thousand items and £11.9m, a rounding error next to the GLP-1 line.

What Happens Next..?

Three things in the licensing and product data are worth watching.

Oral semaglutide for weight. Wegovy tablets were listed in the NHS product dictionary in August 2026 in four strengths. Within weeks the list price moved from £78.48 to £120.00 a pack, a 53% rise. An oral option changes the conversation with patients who will not inject.

Orforglipron. Lilly’s once-daily oral GLP-1 received its UK marketing authorisation on 10 August 2026 and has no NHS product listing yet. The launch is the next event in the class.

Semaglutide generics. Five generic marketing authorisations have now been granted for semaglutide, though no generic pack is listed yet and it remains in Drug Tariff Category C. The SGLT2 class shows what follows. Dapagliflozin went generic, items rose 20% and spend fell 44% in a year. When the first generic semaglutide pack lists, the reimbursement price move usually follows within two or three quarters.

Why This Matters

For NHS budgets, a single drug class has gone from a line item to a quarter of a billion pounds a quarter, and the next wave of oral products is arriving before the first generics have landed. For manufacturers, the field is shifting from supply allocation to share, and share varies enormously by ICB.

For anyone planning in this market, the useful questions are now local ones. Which ICBs are growing fastest, which practices have switched from dulaglutide to tirzepatide, and where the first generic semaglutide will bite.

4th November 2026

|

Gabriel Warwick

Related Articles